권영주(權英珠) 교수

약학과[대학원] /제약산업학과[대학원] /약학부

권영주 프로필 사진
권영주 교수는 약학대학 소속 교수로서 휴스턴대학 화학과에서 분석화학을 전공하였으며, 베일러의대 생화학·분자생물학과에서 박사후연구원으로 화학유전체학 분야의 연구를 수행한 후, 현재 '화학·구조 생물학 연구실(http://ykwon.ewha.ac.kr/)'을 운영하면서, 여성 난치성 암 치료제 개발을 위해 신규 타겟 발굴 및 화학요법제와 표적항암제 개발 및 약물내성 유발 기전 연구 수행, 퇴행성 뇌질환 관련 효소의 이성체 특이적 기능 규명 및 이성체 선택적 억제제 개발 연구 수행, 그리고 비정상적 암 대사와 간질환과의 상관성 규명을 위한 연구를 수행 중이다. 현재까지 총 150여편의 논문을 SCI급 국제학술지에 발표하였고, 11건의 국내외 특허를 등록하였다.
  • 신약개발연구코어센터소장
  • 약학관 B동 101호
  • 02-3277-4653
  • 면담 가능시간
    • 월 4-6시
연구실적
  • A novel A2a adenosine receptor inhibitor effectively mitigates hepatic fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model International Journal of Biological Sciences, 2024, v.20 no.5, 1855-1870
    SCIE Scopus dColl.
  • Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy ACS Nano, 2024, v.18 no.6, 4704-4716
    SCIE Scopus dColl.
  • Cannabidiol, a Regulator of Intracellular Calcium and Calpain Cannabis and Cannabinoid Research, 2023, v.8 no.1, 119-125
    Scopus dColl.
  • Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial Prostate International, 2023, v.11 no.4, 222-227
    SCIE Scopus dColl.
  • Design, synthesis, and biological evaluation of novel HSP27 inhibitors to sensitize lung cancer cells to clinically available anticancer agents Bioorganic Chemistry, 2023, v.130, 106260
    SCIE Scopus dColl.
  • Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure–activity relationships Bioorganic and Medicinal Chemistry, 2023, v.91, 117403
    SCIE Scopus dColl.
  • Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers Journal of Advanced Research, 2023, v.47, 173-187
    SCIE Scopus dColl.
  • Original Article BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2/M arrest, apoptosis, and senescence in a p53-independent manner AMERICAN JOURNAL OF CANCER RESEARCH, 2023, v.13 no.12, 0
    SCIE Scopus dColl.
  • Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells European journal of medicinal chemistry, 2023, v.246, 114999
    SCIE Scopus dColl.
  • Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations Cellular Oncology, 2022, v.45 no.5, 913-930
    SCIE Scopus dColl.
  • An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGF beta R-1 LIFE-BASEL, 2022, v.12 no.11, 1764
    SCIE Scopus dColl.
  • Design, Synthesis, and Cytotoxicity and Topoisomerase I/IIα Inhibition Activity of Pyrazolo[4,3-f]quinoline Derivatives Pharmaceuticals, 2022, v.15 no.4, 399
    SCIE Scopus dColl.
  • Discovery of (E)-3-(3-((2-Cyano-4' -dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.65 no.14, 9974-10000
    SCIE Scopus dColl.
  • Epigenetic regulator Cfp1 safeguards male meiotic progression by regulating meiotic gene expression EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, v.54 no.8, 1098-1108
    SCIE Scopus KCI dColl.
  • Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R EMBO Reports, 2022, v.23 no.8, e52977
    SCIE Scopus dColl.
  • Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors European Journal of Medicinal Chemistry, 2022, v.227, 113916
    SCIE Scopus dColl.
  • The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, v.37 no.30, e235
    SCIE Scopus KCI dColl.
  • Topoisomerase IIα inhibitory and antiproliferative activity of dihydroxylated 2,6-diphenyl-4-fluorophenylpyridines: Design, synthesis, and structure-activity relationships Bioorganic and Medicinal Chemistry Letters, 2022, v.60, 128606
    SCIE Scopus dColl.
  • Topologically-Interlocked Minicircles as Probes of DNA Topology and DNA-Protein Interactions Chemistry - A European Journal, 2022, v.28 no.22, e202200108
    SCIE Scopus dColl.
  • 4-Flourophenyl-substituted 5H-indeno[1,2-b]pyridinols with enhanced topoisomerase II alpha inhibitory activity: Synthesis, biological evaluation, and structure-activity relationships BIOORGANIC CHEMISTRY, 2021, v.116, 105349
    SCIE Scopus dColl.
  • Ak-i-190, a new catalytic inhibitor of topoisomerase ii with anti-proliferative and pro-apoptotic activity on androgen-negative prostate cancer cells International Journal of Molecular Sciences, 2021, v.22 no.20, 11246
    SCIE Scopus dColl.
  • An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma CANCERS, 2021, v.13 no.13, 3221
    SCIE Scopus dColl.
  • Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase II alpha BIOMOLECULES & THERAPEUTICS, 2021, v.29 no.5, 562-570
    SCIE Scopus KCI dColl.
  • COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development Archives of Pharmacal Research, 2021, v.44 no.5, 499-513
    SCIE Scopus KCI dColl.
  • Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase IIα poison European Journal of Medicinal Chemistry, 2021, v.226, 113860
    SCIE Scopus dColl.
  • Drug-like small molecule HSP27 functional inhibitor sensitizes lung cancer cells to gefitinib or cisplatin by inducing altered cross-linked Hsp27 dimers Pharmaceutics, 2021, v.13 no.5, 630
    SCIE Scopus dColl.
  • Identification of Indicators for Preterm Birth Using Retinoid Metabolites METABOLITES, 2021, v.11 no.7, 443
    SCIE Scopus dColl.
  • Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase IIα inhibitors Bioorganic Chemistry, 2021, v.111, 104884
    SCIE Scopus dColl.
  • Bacterial Nucleoside Catabolism Controls Quorum Sensing and Commensal-to-Pathogen Transition in the Drosophila Gut CELL HOST & MICROBE, 2020, v.27 no.3, 345-
    SCIE Scopus dColl.
  • Field-based rational design of p300 histone acetyltransferase inhibitor and systematic evaluation as an anti-fibrotic agent CHEMICAL COMMUNICATIONS, 2020, v.56 no.68, 9795-9798
    SCIE Scopus dColl.
  • Plumbagin Suppresses Pulmonary Fibrosis Via Inhibition of p300 Histone Acetyltransferase Activity JOURNAL OF MEDICINAL FOOD, 2020, v.23 no.6, 633-640
    SCIE Scopus KCI dColl.
  • Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance CANCERS, 2020, v.12 no.6, 1540
    SCIE Scopus dColl.
  • Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, v.20 no.4, 464-475
    SCIE Scopus dColl.
  • A chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform CHEMICAL COMMUNICATIONS, 2019, v.55 no.85, 12857-12860
    SCIE Scopus dColl.
  • Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II alpha-Targeted Chemotherapeutic Agents for Breast Cancer JOURNAL OF MEDICINAL CHEMISTRY, 2019, v.62 no.17, 8194-8234
    SCIE Scopus dColl.
  • Recent therapeutic trends and promising targets in triple negative breast cancer Pharmacology and Therapeutics, 2019, v.199, 30-57
    SCIE Scopus dColl.
  • The synthesis and anticancer activities of chiral epoxy-substituted chromone analogs Bioorganic Chemistry, 2019, v.84, 347-354
    SCIE Scopus dColl.
  • A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships BIOORGANIC & MEDICINAL CHEMISTRY, 2018, v.26 no.18, 5212-5223
    SCIE Scopus dColl.
  • Causes of hyperhomocysteinemia and its pathological significance ARCHIVES OF PHARMACAL RESEARCH, 2018, v.41 no.4, 372-383
    SCIE Scopus KCI dColl.
  • Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors European Journal of Medicinal Chemistry, 2018, v.143, 200-215
    SCIE Scopus dColl.
  • Design, synthesis, and structure-activity relationships of new benzofuro[3,2-b]pyridin-7-ols as DNA topoisomerase II inhibitors Bioorganic and Medicinal Chemistry Letters, 2018, v.28 no.4, 566-571
    SCIE Scopus dColl.
  • Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines BIOORGANIC CHEMISTRY, 2018, v.79, 1-18
    SCIE Scopus dColl.
  • Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/II alpha inhibitors BIOORGANIC & MEDICINAL CHEMISTRY, 2018, v.26 no.18, 5181-5193
    SCIE Scopus dColl.
  • Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells Biochimica et Biophysica Acta - General Subjects, 2018, v.1862 no.5, 1126-1133
    SCIE Scopus dColl.
  • Intestinal P-glycoprotein inhibitors, benzoxanthone analogues JOURNAL OF PHARMACY AND PHARMACOLOGY, 2018, v.70 no.2, 234-241
    SCIE Scopus dColl.
  • Linear diarylheptanoids as potential anticancer therapeutics: synthesis, biological evaluation, and structure-activity relationship studies ARCHIVES OF PHARMACAL RESEARCH, 2018, v.41 no.12, 1131-1148
    SCIE Scopus KCI dColl.
  • Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin DRUG DELIVERY, 2018, v.25 no.1, 1025-1032
    SCIE Scopus dColl.
  • Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase II alpha-targeting anticancer agents BIOORGANIC & MEDICINAL CHEMISTRY, 2018, v.26 no.8, 1909-1919
    SCIE Scopus dColl.
  • 2-Chlorophenyl-substituted benzofuro[3,2-b] pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, v.27 no.15, 3279-3283
    SCIE Scopus dColl.
  • A novel indeno[1,2-b] pyridinone derivative, a DNA intercalative human topoisomerase II alpha catalytic inhibitor, for caspase 3-independent anticancer activity CHEMICAL COMMUNICATIONS, 2017, v.53 no.51
    SCIE Scopus dColl.
  • Antiepileptic and Neuroprotective Effects of Oleamide in Rat Striatum on Kainate-Induced Behavioral Seizure and Excitotoxic Damage via Calpain Inhibition FRONTIERS IN PHARMACOLOGY, 2017, v.8, 817
    SCIE Scopus dColl.
  • BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death Oncology Reports, 2017, v.37 no.1, 579-586
    SCIE Scopus dColl.
  • Design, synthesis and biological evaluation of 1,3-diphenylbenzo[f] [1,7]naphthyrdines BIOORGANIC & MEDICINAL CHEMISTRY, 2017, v.25 no.20, 5586-5597
    SCIE Scopus dColl.
  • Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and II alpha dual inhibitors with DNA non-intercalative catalytic activity EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, v.133, 69-84
    SCIE Scopus dColl.
  • Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells European Journal of Medicinal Chemistry, 2017, v.125, 49-67
    SCIE Scopus dColl.
  • Novel 2-aryl-4-(4′-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors European Journal of Medicinal Chemistry, 2017, v.125, 14-28
    SCIE Scopus dColl.
  • Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor European Journal of Medicinal Chemistry, 2017, v.127, 318-333
    SCIE Scopus dColl.
  • Sensitization of lung cancer cells by altered dimerization of HSP27 Oncotarget, 2017, v.8 no.62, 105372-105382
    SCIE Scopus dColl.
  • Synthesis and biological effect of chrom-4-one derivatives as functional inhibitors of heat shock protein 27 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, v.139, 892-900
    SCIE Scopus dColl.
  • The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection Journal of Natural Products, 2017, v.80 no.8, 2379-2383
    SCIE Scopus dColl.
  • The synthesis of tamoxifen-loaded albumin nanoparticles by homogenizers: Optimization and in vitro characterization Journal of Drug Delivery Science and Technology, 2017, v.41, 20-30
    SCIE Scopus dColl.
  • A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study European Journal of Medicinal Chemistry, 2016, v.113, 228-245
    SCIE Scopus dColl.
  • Calcium influx-mediated translocation of m-calpain induces Ku80 cleavage and enhances the Ku80-related DNA repair pathway ONCOTARGET, 2016, v.7 no.21, 30831-30844
    SCIE Scopus dColl.
  • Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor Bioorganic and Medicinal Chemistry, 2016, v.24 no.8
    SCIE Scopus dColl.
  • Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, v.26 no.7, 1726-1731
    SCIE Scopus dColl.
  • MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation Oncology Reports, 2016, v.35 no.2, 1041-1048
    SCIE Scopus dColl.
  • Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation European Journal of Medicinal Chemistry, 2016, v.121, 433-444
    SCIE Scopus dColl.
  • Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules ONCOTARGET, 2016, v.7 no.33, 53178-53190
    SCIE Scopus dColl.
  • Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and. Heat Shock Protein 90 BIOMOLECULES & THERAPEUTICS, 2016, v.24 no.5, 453-468
    SCIE Scopus dColl.
  • Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents BIOORGANIC CHEMISTRY, 2016, v.66, 145-159
    SCIE Scopus dColl.
  • Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase II alpha catalytic inhibitors EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, v.123, 211-225
    SCIE Scopus dColl.
  • Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones BIOORGANIC & MEDICINAL CHEMISTRY, 2016, v.24 no.22, 5921-5928
    SCIE Scopus dColl.
  • A Series of Novel Terpyridine-Skeleton Molecule Derivants Inhibit Tumor Growth and Metastasis by Targeting Topoisomerases JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.3, 1100-1122
    SCIE Scopus dColl.
  • Benzo[b]Tryptanthrin Inhibits MDR1, Topoisomerase Activity, and Reverses Adriamycin Resistance in Breast Cancer Cells ChemMedChem, 2015, v.10 no.5, 827-835
    SCIE Scopus dColl.
  • Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents Bioorganic and Medicinal Chemistry, 2015, v.23 no.19, 6454-6466
    SCIE Scopus dColl.
  • Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity Bioorganic and Medicinal Chemistry, 2015, v.23 no.1, 160-173
    SCIE Scopus dColl.
  • Modification of 3-arylisoquinolines into 3,4-diarylisoquinolines and assessment of their cytotoxicity and topoisomerase inhibition European Journal of Medicinal Chemistry, 2015, v.92, 583-607
    SCIE Scopus dColl.
  • Modified 2,4-diaryl-5H-indeno[1,2-b]pyridines with hydroxyl and chlorine moiety: Synthesis, anticancer activity, and structure-activity relationship study Bioorganic Chemistry, 2015, v.62, 30-40
    SCIE Scopus dColl.
  • Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases European Journal of Medicinal Chemistry, 2015, v.103, 69-79
    SCIE Scopus dColl.
  • Synthesis and biological activity of 2,4-di- p -phenolyl-6- 2 -furanyl-pyridine as a potent topoisomerase II poison European Journal of Medicinal Chemistry, 2015, v.90, 360-378
    SCIE Scopus dColl.
  • Synthesis and in vitro screening of phenylbipyridinylpyrazole derivatives as potential antiproliferative agents Molecules, 2015, v.20 no.1, 1031-1045
    SCIE Scopus dColl.
  • Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines Bioorganic and Medicinal Chemistry, 2015, v.23 no.13
    SCIE Scopus dColl.
  • Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines Bioorganic and Medicinal Chemistry, 2015, 2015
    SCIE Scopus dColl.
  • Xanthone analogues as potent modulators of intestinal P-glycoprotein EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.93, 237-245
    SCIE Scopus dColl.
  • sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1 alpha signaling pathways ONCOTARGET, 2015, v.6 no.31, 31830-31843
    SCIE Scopus dColl.
  • Cobalt-albumin binding (CAB) assay: An advantageous and flaw free testing of albumin-cobalt binding Journal of Pharmaceutical and Biomedical Analysis, 2014, v.99, 79-82
    Scopus dColl.
  • Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors European Journal of Medicinal Chemistry, 2014, v.82, 181-194
    Scopus SCIE dColl.
  • Development of an Albumin Copper Binding (ACuB) Assay to Detect Ischemia Modified Albumin ANALYTICAL SCIENCES, 2014, v.30 no.10, 985-990
    SCIE Scopus dColl.
  • Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.80 no., 428-438
    SCIE Scopus dColl.
  • Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3, 2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor BIOORGANIC & MEDICINAL CHEMISTRY, 2014, v.22 no.17, 4553-4565
    SCIE Scopus dColl.
  • Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, v.91, 17-23
    SCIE Scopus dColl.
  • Fluorescein Hydrazones as Novel Nonintercalative Topoisomerase Catalytic Inhibitors with Low DNA Toxicity JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.57 no.21, 9139-9151
    SCIE dColl.
  • Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase catalytic inhibitor European Journal of Medicinal Chemistry, 2014, v.90, 302-314
    SCIE Scopus dColl.
  • Reply to the Letter to the Editor "Cobalt-albumin binding (CAB) assay: An advantageous and flaw free testing of albumin-cobalt binding" JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, v.99, 81-82
    SCIE Scopus dColl.
  • Synthesis, antitumor,activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.84, 555-565
    SCIE Scopus dColl.
  • [학술지논문] Cannabidiol, a Regulator of Intracellular Calcium and Calpain CANNABIS AND CANNABINOID RESEARCH , 2023, v.11 no.111 , 1-7
    SCIE
  • [학술지논문] Design, synthesis, and biological evaluation of novel HSP27 inhibitors to sensitize lung cancer cells to clinically available anticancer agents BIOORGANIC CHEMISTRY, 2023, v.130 no.1062600 , 1-11
    SCIE
  • [학술지논문] Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships BIOORGANIC & MEDICINAL CHEMISTRY, 2023, v.91 no.117403 , 1-12
    SCIE
  • [학술지논문] Editorial: Small organic molecules with anticancer activity FRONTIERS IN CHEMISTRY, 2023, v.11 no.2023 , 1-2
    SCIE
  • [학술지논문] Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers JOURNAL OF ADVANCED RESEARCH, 2023, v.47 no.0 , 173-187
    SCIE
  • [학술지논문] Original Article BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2/M arrest, apoptosis, and senescence in a p53-independent manner AMERICAN JOURNAL OF CANCER RESEARCH, 2023, v.13 no.12 , 5887-5900
    SCIE
  • [학술지논문] Roles of Coffee and Its Components in Liver Diseases Drug Targets and Therapeutics, 2023, v.2 no.2 , 133-144
    KCI
  • [학술지논문] Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, v.246 no.114999 , 1-16
    SCIE
  • [학술지논문] An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGF beta R-1 LIFE-BASEL, 2022, v.12 no.11 , 1764-1764
    SCIE
  • [학술지논문] Design, Synthesis, and Cytotoxicity and Topoisomerase I/IIα Inhibition Activity of Pyrazolo[4,3-f]quinoline Derivatives Pharmaceuticals, 2022, v.15 no.4 , 399-399
    SCIE
  • [학술지논문] Epigenetic regulator Cfp1 safeguards male meiotic progression by regulating meiotic gene expression EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, v.54 no.8 , 1098-1108
    SCI
  • [학술지논문] Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R EMBO REPORTS, 2022, v.23 no.8 , 52977-52977
    SCI
  • [학술지논문] Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.227 no.2022 , 113916-113934
    SCI
  • [학술지논문] The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, v.37 no.30 , 235-235
    SCI
  • [학술지논문] Topoisomerase IIα inhibitory and antiproliferative activity of dihydroxylated 2,6-diphenyl-4-fluorophenylpyridines: Design, synthesis, and structure-activity relationships BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, v.60 no.0 , 128606-128606
    SCI
  • [학술지논문] Topologically-Interlocked Minicircles as Probes of DNA Topology and DNA-Protein Interactions CHEMISTRY-A EUROPEAN JOURNAL, 2022, v.28 no.22 , 202200108-202200108
    SCI
  • [학술지논문] 4-Flourophenyl-substituted 5H-indeno[1,2-b]pyridinols with enhanced topoisomerase II alpha inhibitory activity: Synthesis, biological evaluation, and structure-activity relationships BIOORGANIC CHEMISTRY, 2021, v.116 no.2021 , 105349-105360
    SCI
  • [학술지논문] AK-I-190, a New Catalytic Inhibitor of Topoisomerase II with Anti-Proliferative and Pro-Apoptotic Activity on Androgen-Negative Prostate Cancer Cells INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, v.22 no.20 , 11246-11246
    SCIE
  • [학술지논문] An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma CANCERS, 2021, v.13 no.13 , 3221-3246
    SCIE
  • [학술지논문] Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase II alpha BIOMOLECULES & THERAPEUTICS, 2021, v.29 no.5 , 562-570
    SCIE
  • [학술지논문] COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development ARCHIVES OF PHARMACAL RESEARCH, 2021, v.44 no.5 , 499-513
    SCIE
  • [학술지논문] Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase II alpha poison EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, v.226 no.0 , 113860-113860
    SCI
  • [학술지논문] Drug-Like Small Molecule HSP27 Functional Inhibitor Sensitizes Lung Cancer Cells to Gefitinib or Cisplatin by Inducing Altered Cross-Linked Hsp27 Dimers PHARMACEUTICS, 2021, v.13 no.5 , 630-649
    SCIE
  • [학술지논문] Identification of Indicators for Preterm Birth Using Retinoid Metabolites METABOLITES, 2021, v.11 no.7 , 443-443
    SCIE
  • [학술지논문] Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase II alpha inhibitors BIOORGANIC CHEMISTRY, 2021, v.111 no.2021 , 104884-104898
    SCI
  • [학술지논문] Bacterial Nucleoside Catabolism Controls Quorum Sensing and Commensal-to-Pathogen Transition in the Drosophila Gut CELL HOST & MICROBE, 2020, v.27 no.3 , 345-345
    SCI
  • [학술지논문] Field-based rational design of p300 histone acetyltransferase inhibitor and systematic evaluation as an anti-fibrotic agent CHEMICAL COMMUNICATIONS, 2020, v.56 no.68 , 9795-9798
    SCI
  • [학술지논문] Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance CANCERS, 2020, v.12 no.6 , 1-24
    SCIE
  • [학술지논문] Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, v.20 no.4 , 464-475
    SCIE
  • [학술지논문] Recent therapeutic trends and promising targets in triple negative breast cancer PHARMACOLOGY & THERAPEUTICS, 2019, v.199 no.0 , 30-57
    SCI
  • [학술지논문] The synthesis and anticancer activities of chiral epoxy-substituted chromone analogs BIOORGANIC CHEMISTRY, 2019, v.84 no.2019 , 347-354
    SCI
  • [저역서] 의약품기기분석학 동명사, 2023, 496
  • [학술발표] Oncogenic Protein and Its Protein-Protein Interactions: Drug Targetability and Overcoming Therapeutic Resistance Strategies 2023 Annual Meeting and Symposium of The Korea Society of Applied Pharmacology, 대한민국, 2023-10-06 Exploring Novel Therapeutic Approaches for Intractable Diseases through Organoid Models, 2023
  • [학술발표] Targeting the oncogenic role of E74 Like ETS transcription factor 3 (ELF3) through modulation of its protein-protein interaction Targeting the oncogenic role of E74 Like ETS transcription factor 3 (ELF3) through modulation of its, 대한민국, 2023-10-26 Exploring the Frontiers of Pharmaceutical Sciences, 2023
  • [지적재산권] 할로겐 함유 2,4-디페닐 인데노피리딘-5-온 유도체 및 이의 제조방법 국내 : 특허, 등록, 10-2629173, 2024
  • [지적재산권] 신규 화합물 및 그를 유효성분으로 포함하는 약학 조성물 국내 : 특허, 등록, 10-2409583, 2022
강의
  • 2024-2학기

    • 약품기기분석

      • 학수번호 37130분반 01
      • 4학년 ( 3학점 , 3시간) 월 2~2 (약A104) , 화 4~4 (약A400)
      • 학번 1~60
    • 약품기기분석

      • 학수번호 37130분반 02
      • 4학년 ( 3학점 , 3시간) 월 4~4 (포551) , 수 2~2 (약A404)
      • 학번 61~120
    • 의약품분석학Ⅱ

      • 학수번호 39043분반 01
      • 2학년 ( 3학점 , 3시간) 월 5~5 (포551) , 화 2~2 (약A404)
      • 전공필수
  • 2023-2학기

  • 2023-1학기

  • 2022-2학기

    • 약품분석II

      • 학수번호 33963분반 01
      • 3학년 ( 3학점 , 3시간) 월 2~2 (약A400) , 수 3~3 (약A404)
      • 전공필수
    • 약학실습I

      • 학수번호 37105분반 01
      • 3학년 ( 1.5학점 , 3시간) 월 6~9 (약A300)
      • 전공필수 팀티칭, 학번 61-80, 집중이수(8주) 수업
    • 약학실습I

      • 학수번호 37105분반 02
      • 3학년 ( 1.5학점 , 3시간) 화 6~9 (약A300)
      • 전공필수 팀티칭, 학번 81-100, 집중이수(8주) 수업
    • 약학실습I

      • 학수번호 37105분반 03
      • 3학년 ( 1.5학점 , 3시간) 수 6~9 (약A300)
      • 전공필수 팀티칭, 학번 101-120, 집중이수(8주) 수업
    • 약품기기분석

      • 학수번호 37130분반 01
      • 4학년 ( 3학점 , 3시간) 월 4~4 (약A404) , 화 2~2 (약A104)
      • 팀티칭
    • Lab rotation Ⅰ

      • 학수번호 38927분반 01
      • 1학년 ( 1.5학점 , 0시간) 목 7~7
      • 팀티칭
    • Lab rotation Ⅰ

      • 학수번호 38927분반 02
      • 1학년 ( 1.5학점 목 7~7
      • 팀티칭
    • Lab rotation Ⅰ

      • 학수번호 39032분반 01
      • 1학년 ( 1.5학점 , 0시간) 목 7~7
      • 팀티칭
  • 2022-1학기

    • 약품분석I

      • 학수번호 33502분반 01
      • 3학년 ( 3학점 , 3시간) 월 2~2 (약A100-1) , 수 2~2 (약A400)
      • 전공필수
    • 약학실습I

      • 학수번호 37105분반 01
      • 3학년 ( 1.5학점 , 3시간) 화 6~7 (약A300)
      • 전공필수 팀티칭/ 학번 1~20
    • 약학실습I

      • 학수번호 37105분반 02
      • 3학년 ( 1.5학점 , 3시간) 수 6~7 (약A300)
      • 전공필수 팀티칭/ 학번 21~40
    • 약학실습I

      • 학수번호 37105분반 03
      • 3학년 ( 1.5학점 , 3시간) 월 6~7 (약A300)
      • 전공필수 팀티칭/ 학번 41~60
    • 신약개발세미나및실습III

      • 학수번호 G16849분반 01
      • 학년 ( 3학점 , 3시간) 목 7~8
    • 신약개발세미나및실습Ⅲ

      • 학수번호 G18240분반 01
      • 학년 ( 3학점 , 3시간) 목 7~8
  • 2021-2학기

    • 약품분석II

      • 학수번호 33963분반 01
      • 3학년 ( 3학점 , 3시간) 월 3~3 , 수 3~3
      • 전공필수
    • 약품분석II

      • 학수번호 33963분반 02
      • 3학년 ( 3학점 , 3시간) 월 5~5 , 수 4~4
      • 전공필수
    • 약학실습I

      • 학수번호 37105분반 01
      • 3학년 ( 1.5학점 , 3시간) 월 6~9 (약A300)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 66-86
    • 약학실습I

      • 학수번호 37105분반 02
      • 3학년 ( 1.5학점 , 3시간) 화 6~9 (약A300)
      • 전공필수 집중이수(8주) 수업,, 팀티칭, 학번 87-108
    • 약학실습I

      • 학수번호 37105분반 03
      • 3학년 ( 1.5학점 , 3시간) 수 6~9 (약A300)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 109-130, 산업제약학과 04반과 합반
    • 약학실습I

      • 학수번호 37105분반 04
      • 3학년 ( 1.5학점 , 3시간) 수 6~9 (약A300)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 약학과 03반과 합반
    • 약품기기분석

      • 학수번호 37130분반 01
      • 4학년 ( 3학점 , 3시간) 월 4~4 , 목 3~3
      • 팀티칭
    • 약품기기분석

      • 학수번호 37130분반 02
      • 4학년 ( 3학점 , 3시간) 화 5~5 , 목 4~4
      • 산업제약학과 03분반과 합반
    • 심화실습및연구Ⅰ

      • 학수번호 37154분반 01
      • 6학년 ( 4학점
      • 전공필수
    • Honors research

      • 학수번호 37803분반 01
      • 4학년 ( 1학점 , 1시간)
      • 산업제약학과 02분반과 합반
  • 2021-1학기

    • 약품분석I

      • 학수번호 33502분반 01
      • 3학년 ( 3학점 , 3시간) 월 2~2 , 수 3~3
      • 전공필수
    • 약학실습I

      • 학수번호 37105분반 01
      • 3학년 ( 1.5학점 , 3시간) 화 6~7 (약A300)
      • 전공필수 팀티칭/ 학번 1~22
    • 약학실습I

      • 학수번호 37105분반 02
      • 3학년 ( 1.5학점 , 3시간) 월 6~7 (약A300)
      • 전공필수 팀티칭/ 학번 23~43
    • 약학실습I

      • 학수번호 37105분반 03
      • 3학년 ( 1.5학점 , 3시간) 수 6~7 (약A300)
      • 전공필수 팀티칭/ 학번 44~65
    • Honors research

      • 학수번호 37803분반 01
      • 4학년 ( 1학점 , 1시간)
      • 산업제약학과 02반과 합반
경력

신약개발연구코어센터소장 2021-12-01 ~ 2025-07-31